Announcement PDF Emyria ASX Announcement | 11 June 2026 ASX RELEASE. 11 June 2026 Emyria Company Update Presentation Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to provide a Company Update which will be presented at the Gold Coast Investment Showcase on 11 June 2026. The update includes Company progress to date and new information on clinic establishment timelines and projected breakeven for a stand alone clinic. Attached is the Company Update. This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 436 363 | investors@emyria.com ASX RELEASE Emyria ASX Announcement | 11 June 2026 2 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs Advanced therapies. Compassionate care. 1 ASX : EMD Delivering the new paradigm in mental health care June 2026 Company Update Advanced therapies. Compassionate care. 2 Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions. This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Advanced therapies. Compassionate care. 3 Emyria is building a national network of clinics specialising in delivery of Psychedelic Assisted Therapy for PTSD and Treatment Resistant Depression. Who are we? Emyria is addressing a significant and escalating gap in the mental healthcare market Advanced therapies. Compassionate care. 4 Significant momentum in psychedelic drug treatments SOURCES 1. https://psychedelics.berkeley.edu/clinical-trials-map Emyria is well positioned to leverage this momentum, writing the playbook for psychedelic drug delivery Recent macro catalysts provide significant tailwinds for Emyria Advanced therapies. Compassionate care. 5 Worldwide first mover advantage A Regulated Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions SOURCES 1 .https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists MDMA-assisted therapy For PTSD Psilocybin-assisted therapy For Depression Australia is the FIRST jurisdiction in the world to reschedule two promising treatments1 This regulation change has created a Significant Market Opportunity. Advanced therapies. Compassionate care. 6 SCREENING AND PREPARATION ACTIVE TREATMENT PROTOCOL FOLLOW-UP Dosing Day 1 (8 hrs) Each dosing day ~$10,000 revenue PTSD Total treatment cost / patient ~$33,000 Treatment Resistant Depression cost / patient ~$22,000 Patient journey I Treatment model + bed capacity Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up Dosing Day 2 (8 hrs) Dosing Day 3 (8 hrs) PTSD only ~6-12 weeks ~4-6 weeks 12 months Clinic Beds Dosing days / week Perth (x2) 8 40 Brisbane 3 15 Melbourne 3 15 Sydney 4 20* = 18 90 *When operational BED CAPACITY Significant Total Addressable Market ~1,100,000 adults in Australia have major depression (~4%) ~1,500,000 adults in Australia have PTSD (~7%) Advanced therapies. Compassionate care. 7 Emyria’s PTSD program is delivering durable and lasting results Durable symptom and quality of life improvement, beyond 12 months SOURCES: 1. The PCL-5 is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to diagnostic DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition). Baseline Cycle 1 Cycle 2 Cycle 3 6 months after end of treatment 12 months after end of treatment Average PCL-5 1 Scores by Visit (up to 12 months follow-up) Typical last treatment Patients continue to improve after active treatment has ended. >66% of patients no longer meet criteria for PTSD diagnosis Emyria Real-World Data as of Dec 31st 2025 ~76% of patients have a clinically significant improvement Advanced therapies. Compassionate care. 8 Major Funders are spending Hundreds of Millions each year on mental health Private Health Insurers Department of Veterans’ Affairs Other Insurers $2B spent by Medibank on mental health hospitalisations in last 10 years, $219M/yr in 2024 alone. 1 The Government spends on veteran mental health each year. 2 $300M/yr Almost three in four (veterans) are estimated to have met criteria for a mental disorder at some stage in their lifetime. 3 Life insurers … paid out more than for retail mental health claims in 2024 4 $2.2B in 2024 SOURCES: 1. https://www.heraldsun.com.au/health/mental-health/alarming-research-shows-extent-of-mental-health-crisis-in-australia/news-story/66f6937a316f9dd54673c5a6f692b232 2. https://www.dva.gov.au/sites/default/files/twrp_mhpr.pdf 3. https://www.dva.gov.au/news/latest-stories/report-hospitalisations-suicidality-and-self-harm-released#:~:text=The%20Australian%20Government%20is%20committed,%E2%80%93%20Veterans%20&%20Families%20Counselling%20Service. 4. https://www.abc.net.au/news/2025-07-16/spike-in-mental-health-illness-claims-super-funds-delay-payouts/105531022 Only 26% of insured adults Advanced therapies. Compassionate care. 9 1 Time (months) 2 3 4 5 6 7 8 9 10 11 12 Sources: 1. Costs are estimated based on estimates of direct clinician time required to delivery program 2. Standard of care costs based on conversations with clinical specialists. WA East Metropolitan Health Service reported Specialised Mental Health Care Days average cost of $2,156 per day in FY 2022 / 2023 (https://annualreport.emhs.health.wa.gov.au/key-performance-indicators/browse-kpis/average-cost-per-bed-day-in-specialised-mental-health-inpatient-services/) 3. Marseille E, et al. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS One. 2020 Oct 14;15(10):e0239997. doi: 10.1371/journal.pone.0239997. PMID: 33052965; PMCID: PMC7556534. MDMA-AT cost 1 vs standard of care for PTSD 2, 3 Cumulative costs ($1,000s of AUD) 10 20 30 40 50 60 2-week hospital admission 2 (~$24,500) Neurostimulation (~$3,000) Ongoing care Screening Emyria’s program Emyria’s intensive, 6-12 week program 1 Typical standard of care interventions 2 Multidisciplinary follow-up for 12m ~ $33,000 / yr 1 ~ $60,000 / yr 2 Studies show durability of MDMA-AT benefit holds out to at least 12m 3 4-week group therapy program (~$3,000) Regular specialist appointments (~$500 / each) 2-week hospital admission 2 (~$24,500) Advanced therapies. Compassionate care. 10 Key funding bodies1,2 Other ad hoc approvals Work in progress Third party funding Reimbursement has commenced for Psychedelic Assisted Therapy Case by case approvals have occurred from other funding bodies We continue to engage other private health insurers, workers compensation insurers and other funding bodies SOURCES: 1. See ASX announcement 18 June 2025 2. See ASX announcement 20 November 2025 Advanced therapies. Compassionate care. 11 Investment Phase Revenue Generation Projected break-even point Months 1-3 Months 4-6 Months 6-9 Months 9-12+ Clinic set-up Open clinic & commence screening Dosing day ramp-up Optimise dosing day utilisation Fit-out & recruitment commences Typical timeline to projected clinic profitability Current Clinic Status Sydney Perth Clinic Brisbane Mornington (VIC) Advanced therapies. Compassionate care. 12 Maturing clinic I Perth Clinic dosing days May 2025 to June 2026 * Monthly stand alone clinic breakeven. Seasonal Impact - Christmas Seasonal Impact –Easter Advanced therapies. Compassionate care. 13 Regulatory confidence is building TGA recommendations grow the pool of therapists that Emyria can recruit SOURCES: 1. Refer to ASX announcement 28 May In May 26 TGA relaxed rules to include Nurses and Occupational Therapists as a “lead” PAT therapist 1 Minimum therapist requirement Clinical Psychologist Existing Medical Doctor Existing Nurse with mental health experience NEW Occupational Therapist with mental health experience NEW Psychologists Lobbying ongoing Advanced therapies. Compassionate care. 14 Authorised Prescribers Highly defensible healthcare business Third Party Funding Fit-for- Purpose Facilities Proven Clinical Model Skilled Therapists Secure Drug Supply Advanced therapies. Compassionate care. 14 Advanced therapies. Compassionate care. 15 Scalable contractor workforce Therapists trained and contracted Authorised Prescribers (AP) Perth (x2) ~35 8 approved 1 in application stage Brisbane ~25 3 approved 2 in application stage Melbourne ~25 1 approved 3 in application stage Sydney ~30 to attend June training 4 in application stage Capital light and flexible workforce to support growing clinic utilisation Emyria provides a specialised training and regulatory pathway for psychiatrists and therapists Advanced therapies. Compassionate care. 16 Potential future treatable conditions SOURCES 1. https://psychedelics.berkeley.edu/clinical-trials-map Significant global research in psychedelic drugs New Treatable Conditions Increase Total Addressable Market Advanced therapies. Compassionate care. 17 Emyria has established versatile delivery infrastructure Infrastructure able to support growing, global research effort into psychedelic drugs More treatment types Can support future potential indications and treatment types for patients. Third party clinical trials Can support clinical trials delivery required for new indications, supporting global drug development efforts; increasing clinic utilisation and adding a further revenue stream1. Emyria’s psychedelic assisted therapy delivery playbook in action SOURCES 1. See ASX announcement 20 April 2026 Advanced therapies. Compassionate care. 18 Emyria Board Significant Clinical Services & Global Innovation Expertise Greg Hutchinson Executive Chairman Health Service Leadership: 5D Clinics Former CEO Sonic HealthPlus leading 40+ clinics Dr Michael Winlo Executive Director Research & Data Expertise: Ex-Palantir healthcare lead, Medical Doctor and Stanford MBA Dr Karen Smith Non-Executive Director Biopharma Executive: 100+ clinical trials and 20+ regulatory approvals; Former Chief Medical Officer and Global Head of R&D at Jazz Pharma Dr Mohit Kaushal Non-Executive Director Health IT Strategist: Key role in Oak Street Health's $10.6B acquisition by CVS Health; Served in Obama’s Health IT task force; Adjunct Professor at Stanford Prof Sir John Tooke Non-Executive Director Clinical Service & Health Payer Expertise: Former President of the Academy of Medical Sciences, influential roles at BUPA and past advisor to Google DeepMind Advanced therapies. Compassionate care. 19 ASX: EMD Trading Information Last Traded Share Price A$0.043 12-Month low / high A$0.021 / 0.078 Shares Outstanding 806,483,233 Unlisted Options (including loyalty options) 310,147,902 Market Capitalisation 1 ~A$35m Last Cash Position 2 ~A$9m NOTES: 1. As of market close 5 June 2026 2. As reported in March 2026 Quarterly Report Substantial Shareholder Shareholder % #1 Holder: Greg Hutchinson, Exec. Chairman 5.29% Shareholding Top 50 Share Price, trading history Corporate Overview Advanced therapies. Compassionate care. 20 First mover advantage globally Significant Total Addressable Market AUS + globally Generating revenue Developing the P-AT playbook Capital Light approach to clinics expansion Delivering durable outcomes Emyria | Summary Advanced therapies. Compassionate care. 21 Advanced therapies. Compassionate care. Emyria (ASX:EMD) | Executing strongly Delivering on commitments to shareholders Recent Achievements • 1st Private Health Insurer Funding treatments (Medibank) • Opened 2nd Perth Empax Clinic • Opened Brisbane Empax Clinic • Opened Mornington (Victoria) Clinic • Published 12 month Data Outcomes • Commenced Empax Global Partnership Program (EGPP) • Confirmed First Sydney Clinic Future Drivers: • 1st DVA approval • Open Sydney Clinic • Additional New Sites Confirmed • New Funders Confirmed • Potential New Indications • 2nd Partner for Empax GPP • Leveraging scalable IP to create global partnerships 21 Contact Information Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Investor / Media Inquiries investors@emyria.com Visit Our Investor Hub